Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Advances in Personalized Treatment of Cancer (Powered By: 4oncommunity)
share announcement

Advances in Personalized Treatment of Cancer (Powered By: 4oncommunity)

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: closed (20 July 2023) | Viewed by 6215

Special Issue Editors

Prof. Dr. Matteo Fassan

E-Mail Website
Guest Editor
Department of Medicine, Surgical Pathology Unit, University of Padua, Padua, Italy
Interests: gastrointestinal pathology; molecular pathology; preinvasive lesions; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Umberto Malapelle

E-Mail Website
Guest Editor
Department of Public Health, University of Naples Federico II, Naples, Italy
Interests: predictive molecular pathology in solid tumors; next generation technologies in molecular biology; liquid biopsies; predictive oncology
Special Issues, Collections and Topics in MDPI journals
Dr. Nicola Fusco

E-Mail Website
Guest Editor
1. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
2. Division of Pathology, IRCCS European Institute of Oncology (IEO), Milan, Italy
Interests: translational research; breast cancer; biomarkers; immunology; molecular pathology; TILs; precision medicine
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Fabio Pagni

E-Mail Website
Guest Editor
School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 28, 20900 Monza, Italy
Interests: thyroid carcinoma
Special Issues, Collections and Topics in MDPI journals
Dr. Carmen Criscitiello

E-Mail Website
Guest Editor
New Drugs and Early Drug Development for Innovative Therapies Division, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy
Interests: breast cancer; new drugs; clinical trials; translational research; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Dr. Sara Pilotto

E-Mail Website
Guest Editor
Department of Medicine, University of Verona, P.le L.A. Scuro 10, 37134 Verona, Italy
Interests: lung cancer; translational research; chemotherapy; targeted therapy; immunotherapy; methodology of clinical trials; nutrition; physical activity and psychological aspects of cancer patients

Special Issue Information

Dear Colleagues, 

We are experiencing an amazing era of advances in the diagnosis and treatment of cancer. In this evolving scenario, predictive molecular pathology is called to face new challenges. Our increased diagnostic resolution, coupled with the integration of clinicopathologic information, and big molecular data, is allowing for a growth in the selective capacity of molecular targeted treatments. Novel biomarkers at genomic, transcriptomic, proteomic, and immunologic levels have been discovered, and more accurate testing methods and guidelines are expected. These biomarkers are strongly impacting treatment decision making in patients with cancer.

4oncommunity is a platform that systematizes the growing amount of information regarding precision medicine, but also a virtual space in which to share experiences and knowledge for the advancement of the oncology community.

This Special Issue is edited by the Scientific Board of 4oncommunity (www.4oncommunity.com Twitter: @4oncommunity) to provide a comprehensive portrait of the current state of knowledge of biomarkers for the clinical management of cancer patients. One of the aims of this initiative is to foster a novel approach in collaborating between scientists working on cancer. We especially welcome review articles (either systematic or discursive), original translational research studies, and short communications.

Prof. Dr. Matteo Fassan
Dr. Umberto Malapelle
Prof. Dr. Nicola Fusco
Prof. Dr. Fabio Pagni
Dr. Carmen Criscitiello
Dr. Sara Pilotto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • biomarkers
  • precision medicine
  • pathology
  • molecular pathology
  • oncology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 4283 KiB  
Article
Survival Impact of Long-Term Tramadol Use on Breast Cancer for Patients with Chronic Pain: A Propensity Score-Matched Population-Based Cohort Study
by Mingyang Sun, Chia-Lun Chang, Chang-Yun Lu, Szu-Yuan Wu and Jiaqiang Zhang
J. Pers. Med. 2022, 12(3), 384; https://doi.org/10.3390/jpm12030384 - 02 Mar 2022
Cited by 1 | Viewed by 2789
Abstract
Purpose: The impact of tramadol analgesic use before breast cancer diagnosis on survival in patients with chronic pain is unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the breast cancer-related survival of patients with chronic pain who received long-term [...] Read more.
Purpose: The impact of tramadol analgesic use before breast cancer diagnosis on survival in patients with chronic pain is unclear. Therefore, we designed a propensity score-matched population-based cohort study to compare the breast cancer-related survival of patients with chronic pain who received long-term tramadol analgesic treatment with that of those who did not receive such treatment. Patients and Methods: We included patients with chronic pain and categorized them into two groups according to their analgesic use, comparing their breast cancer-related survival; patients with breast cancer and chronic pain who were prescribed ≥180 defined daily doses (DDDs) of tramadol analgesics per year >3 months before breast cancer diagnosis comprised the case group, and those who were prescribed non-tramadol analgesics before breast cancer diagnosis comprised the control group. Patients in both groups were matched at a ratio of 1:5. Results: The matching process yielded a final cohort of 624 patients (104 and 520 in the case and control groups, respectively) who were eligible for further analysis. According to both univariate and multivariate Cox regression analyses, the adjusted hazard ratio for all-cause death in the case group compared with in the control group was 3.45 (95% confidence interval = 2.36–5.04; p < 0.001). Conclusion: Long-term tramadol analgesic use prior to breast cancer diagnosis might be associated with poor overall survival in patients with chronic pain compared with such patients that did not receive long-term tramadol analgesic treatment. Full article
(This article belongs to the Special Issue Advances in Personalized Treatment of Cancer (Powered By: 4oncommunity))
►▼ Show Figures

Figure 1

12 pages, 1163 KiB  
Article
Pre-Treatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Occult Cervical Metastasis in Clinically Negative Neck Supraglottic and Glottic Cancer
by Giovanni Salzano, Francesco Perri, Fabio Maglitto, Giulia Togo, Gianluca Renato De Fazio, Michela Apolito, Federica Calabria, Claudia Laface, Luigi Angelo Vaira, Umberto Committeri, Mario Balia, Ettore Pavone, Corrado Aversa, Francesco Antonio Salzano, Vincenzo Abbate, Alessandro Ottaiano, Marco Cascella, Mariachiara Santorsola, Roberta Fusco, Luigi Califano and Franco Ionnaadd Show full author list remove Hide full author list
J. Pers. Med. 2021, 11(12), 1252; https://doi.org/10.3390/jpm11121252 - 25 Nov 2021
Cited by 4 | Viewed by 1700
Abstract
Background. Among patients with diagnosis of Laryngeal Squamous Cell Carcinoma (LSCC), up to 37.5% of cases may have occult metastasis (OM), and this feature is linked to poor prognosis and high rate of local recurrence. The role of elective neck dissection (END) in [...] Read more.
Background. Among patients with diagnosis of Laryngeal Squamous Cell Carcinoma (LSCC), up to 37.5% of cases may have occult metastasis (OM), and this feature is linked to poor prognosis and high rate of local recurrence. The role of elective neck dissection (END) in clinically negative neck (cN0) LSCC remains controversial. It is of great value to search for low-cost and easily detectable indicators to predict the risk of OM in laryngeal cancer. Recent reports have shown that high values of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) represent a negative prognostic factor in head and neck cancers. The aim of our study has been to investigate the value of pre-treatment NLR and PLR with regard to predicting occult cervical metastasis in cN0 supraglottic and glottic LSCC. Materials and methods. Data of patients affected by LSCC, who had been surgically treated by means of laryngectomy (total, horizontal partial and supracricoid) and END between January 2006 and January 2021, were retrospectively reviewed, using information retrieved from a database dedicated to such procedures in a single tertiary care referral institute. Results. A total of 387 patients were treated for LSCC at our Institute from 2006 to 2021, but only 108 of them met the inclusion criteria. The median age at the time of diagnosis was 64 years (range, 39–89 years). All the tumors were treated with a laryngectomy and an END. A total of 27.7% of patients were found positive for neck node metastasis (the pN+ group), while 78/108 (72.3%) patients were found to be negative for the presence of neck metastasis (the pN0 group). High values of NLR, but not PLR, significantly correlated with the probability of OM, and according to the iterative algorithm of Newton–Raphson, an NLR value of 2.26 corresponds to a probability of OM of 20%. Conclusion. Our analysis revealed a statistical correlation between high NLR pre-treatment values and positive neck OM in patients with LSCC. Full article
(This article belongs to the Special Issue Advances in Personalized Treatment of Cancer (Powered By: 4oncommunity))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop